Taiho Oncology Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAIHO ONCOLOGY, and when can generic versions of TAIHO ONCOLOGY drugs launch?
TAIHO ONCOLOGY has two approved drugs.
There are nine US patents protecting TAIHO ONCOLOGY drugs.
There are one hundred and sixty-five patent family members on TAIHO ONCOLOGY drugs in thirty-five countries and twenty supplementary protection certificates in fourteen countries.
Drugs and US Patents for Taiho Oncology
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | AB | RX | Yes | No | 10,456,399 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | AB | RX | Yes | Yes | 9,943,537 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | AB | RX | Yes | No | RE46284 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Taiho Oncology
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | 5,744,475 | ⤷ Try a Trial |
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | 6,479,500 | ⤷ Try a Trial |
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | 5,744,475 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Taiho Oncology Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20140080551 | ⤷ Try a Trial |
Poland | 3042669 | ⤷ Try a Trial |
South Africa | 201805245 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Taiho Oncology Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1849470 | CA 2017 00036 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427 |
1849470 | 122017000052 | Germany | ⤷ Try a Trial | PRODUCT NAME: TRIFLURIDIN IN KOMBINATION MIT TIPIRACIL ODER EINEM SALZ VON TIPIRACIL WIE TIPIRACIL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1096 20160425 |
2657233 | CR 2023 00036 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.